What Artivion’s recent share performance suggests for investors
Artivion (AORT) has attracted attention after a recent share price pullback, with the stock down around 7% over the past month and about 24% over the past 3 months from a last close of US$35.70.
See our latest analysis for Artivion.
Recent trading has been weak, with a 30 day share price return of about a 7% decline and a 90 day share price return of about a 24% decline. However, the 1 year total shareholder return of around 45% and 3 year total shareholder return near 3x still point to strong longer run gains, suggesting momentum has faded recently even after substantial value creation over time.
If Artivion’s mixed momentum has you thinking about diversification, this could be a good moment to scan the market using a healthcare focused AI stocks screener such as 36 healthcare AI stocks
With Artivion reporting annual revenue of about US$441.33 million and net income of roughly US$9.76 million, plus a sizeable gap to analyst price targets, the key question is whether the recent pullback signals an undervalued opportunity or if the market is already pricing in future growth.
Most Popular Narrative: 31% Undervalued
Artivion’s most followed valuation narrative pegs fair value at about $51.43 per share, well above the last close of $35.70. This puts the current pullback in a different light for anyone focused on long term cash flows.
Continued progress in obtaining regulatory approvals and launching products (e.g., BioGlue in China, Arcevo LSA pivotal trial in the U.S., and potential NEXUS approval via Endospan acquisition) is extending Artivion's geographic reach and product offerings. This is unlocking new growth regions and revenue streams while further diversifying earnings.
Want to see what sits behind that valuation gap? The narrative leans heavily on sustained revenue expansion, rising margins and a future earnings multiple that assumes meaningful execution. Curious how those moving parts add up to the current fair value line.
Result: Fair Value of $51.43 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, recent analyst commentary flags that a slightly higher discount rate, which indicates higher perceived risk, and tighter margin expectations could quickly chip away at that valuation gap.
Find out about the key risks to this Artivion narrative.
Another way to look at Artivion’s valuation
The earlier narrative leans on future earnings and a high implied P/E in 2028 to argue that Artivion looks undervalued at $35.70. Yet on a simple P/S basis of 3.9x, the shares screen as expensive versus the fair ratio of 2.4x, peers at 3.5x and the US Medical Equipment industry at 2.7x. That gap suggests less room for error if growth or margins come in below expectations, so which story do you think carries more weight right now?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Mixed signals on valuation and sentiment so far? Take a closer look at the numbers, weigh both sides, and decide how you feel about Artivion’s balance of 3 key rewards and 1 important warning sign
Looking for more investment ideas?
If Artivion has sharpened your focus, do not stop here. Broaden your watchlist now so you are not late to the next opportunity.
- Spot potential turnarounds early by scanning 30 elite penny stocks with strong financials that pair low share prices with stronger financial profiles than many would expect.
- Zero in on quality at a discount by using the 58 high quality undervalued stocks to surface companies with solid fundamentals trading below their estimated worth.
- Prioritise resilience and sleep a little easier by checking the 73 resilient stocks with low risk scores focused on businesses with more measured risk profiles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com